Orthocell Ltd (AU:OCC) has released an update.
Orthocell Ltd announced a strong financial quarter with a 19% increase in revenue to $1.61 million, driven by new product sales and marking a 40.7% year-to-date revenue jump. The company completed a $3.5 million strategic placement, boosting its cash balance to $20.1 million, and is on track for U.S. approval of its nerve repair device, Remplir™, in early 2025. Orthocell also strengthened its leadership by adding former Australian diplomat Hon Kim Beazley AC to its Board.
For further insights into AU:OCC stock, check out TipRanks’ Stock Analysis page.
